

## press release

### **Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model**

- Hims & Hers customers will soon have access to FDA-approved injectables Ozempic® and Wegovy®, and Wegovy® pill, the first and only oral GLP-1 approved for weight loss, at Novo Nordisk's self-pay prices
- The Company welcomes the decision of Hims & Hers to shift its GLP-1 business model towards FDA-approved medicines
- Novo Nordisk's focus remains on delivering innovation, powered by our distinct semaglutide molecule, to US consumers, meeting people wherever they choose to get their care

**Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026** – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take effect later this month. Under the terms of the agreement, Hims & Hers will offer access to FDA-approved Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg and Wegovy® (semaglutide) tablets 1.5 mg, 4 mg, 9 mg, and 25 mg and injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, to US consumers at the same affordable self-pay prices as other telehealth platforms. We welcome Hims & Hers shifting their GLP-1 business model to focus on increasing access to affordable, branded FDA-approved medicines. Hims & Hers will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved alternatives when clinically appropriate in consultation with a healthcare professional.

“This agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy,” said Mike Doustdar, President and CEO of Novo Nordisk. “Wegovy® is not simply an obesity therapy. It is a clinically proven treatment that helps adults with obesity lose weight while also reducing the risk of cardiovascular events in patients who also have heart disease. That combination of powerful weight loss efficacy and proven risk reduction is what makes Wegovy® truly distinct. We all want better health. Our goal is simple: ensure that every patient who can benefit from our medicines has the opportunity to access them, wherever they choose to receive care.”

Patients using Hims & Hers will soon have access to the full range of FDA-approved semaglutide medicines, including the Wegovy® pill which delivers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials. All doses of Ozempic® (injectable) and Wegovy® (injectable and pill) are broadly available nationwide for Americans across 70,000+ pharmacies, our own direct-to-consumer platform, NovoCare® Pharmacy, and select telehealth providers and digital platforms.

In OASIS 4, Wegovy® pill demonstrated an average weight loss of about 17% (16.6%), when used along with a reduced-calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.\*<sup>1</sup> When looking at the efficacy regardless of if all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy® pill compared to about 2% (2.4%) for placebo.\*\*<sup>1</sup> Common adverse reactions were similar to those previously seen in clinical trials with Wegovy® (semaglutide) injection 2.4 mg, including nausea, diarrhea, and vomiting.<sup>1</sup>

Along with diet and exercise, Wegovy® pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease.

Ozempic® is approved for adults with type 2 diabetes along with diet and exercise to improve blood sugar control and to reduce the risk of MACE such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

In light of this agreement, Novo Nordisk is dismissing our patent infringement lawsuit against Hims & Hers while reserving the right to refile in the future.

\* Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies.

\*\* Based on the treatment policy estimand: treatment effect regardless of if patients stayed on treatment or took other weight loss therapies.

#### **About OASIS 4**

OASIS 4 was a 64-week phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) or overweight (BMI  $\geq 27$  kg/m<sup>2</sup>) with one or more weight-related comorbidities.<sup>1</sup> People with diabetes were excluded.<sup>1</sup> OASIS 4 included a 64-week treatment period, including a 12-week dose escalation, and a 7-week off-treatment follow-up period.

In total, 307 participants were randomized in a 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention for 64 weeks.<sup>1</sup>

For those taking Wegovy® pill, 76% achieved 5% or greater body weight loss (from a baseline body weight of 235 lb.) versus 31% taking placebo (from a baseline body weight of 231 lb.).<sup>1</sup>

## What is Wegovy®?

Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg (the latter currently approved only in the EU) and Wegovy® (semaglutide) tablets 25 mg (currently available in the US only) are prescription medicines used with a reduced-calorie diet and increased physical activity to reduce the risk of major cardiovascular events such as death, heart attack or stroke in adults with known heart disease and with either obesity or overweight. Moreover, Wegovy® helps adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems, to lose weight and keep the weight off.

*Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 68,800 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in eight states plus Washington, D.C. For more information, visit [novonordisk.com](http://novonordisk.com) and [novonordiskus.com](http://novonordiskus.com), and follow us on [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).*

## Contacts for further information

### Media:

#### Liz Skrbkova (US)

+1 609 917 0632

[USMediaRelations@novonordisk.com](mailto:USMediaRelations@novonordisk.com)

#### Ambre James-Brown (Global)

+45 3079 9289

[Globalmedia@novonordisk.com](mailto:Globalmedia@novonordisk.com)

### Investors:

#### Frederik Taylor Pitter (US)

+1 609 613 0568

[fptr@novonordisk.com](mailto:fptr@novonordisk.com)

#### Michael Novod

+45 3075 6050

[nvno@novonordisk.com](mailto:nvno@novonordisk.com)

#### Jacob Martin Wiborg Rode (Global)

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

#### Sina Meyer (Global)

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)

#### Christoffer Sho Togo Tullin (Global)

+45 3079 1471

[cftu@novonordisk.com](mailto:cftu@novonordisk.com)

#### Max Ung (Global)

+45 3077 6414

[mxun@novonordisk.com](mailto:mxun@novonordisk.com)

#### Alex Bruce (Global)

+45 34 44 26 13

[axeu@novonordisk.com](mailto:axeu@novonordisk.com)

**References:** 1. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. *N Engl J Med.* 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.